

5th INTERNATIONAL CONFERENCE ON FUTURE TRENDS IN THE TREATMENT OF BRAIN TUMORS

November 8th- 9th 2013, Hotel Royal Carlton, Bologna (Italy)



CHAIRPERSON
Alba A. Brandes

SCIENTIFIC COMMITTEE

Antonella Bacci
Damiano Balestrini
Stefania Bartolini
Marco Bartolotti
Claudio Degli Esposti
Antonio Fioravanti
Enrico Franceschi
Maria Pia Foschini
Gianluca Marucci
Roberto Michelucci
Rosalba Poggi
Eugenio Pozzati
Patrizia Riguzzi
Giovanni Tallini
Alicia Tosoni

SCIENTIFIC SECRETARIAT



Via Aosta 4/A - 20155 Milan (Italy)
PHONE: + 39 02 5416951
FAX: + 39 02 54169554
E-mail: segreteria@complete-italy.it

ORGANIZING SECRETARIAT

AIM GROUP INTERNATIONAL
AIM Travel S.r.l.

Via G. Ripamonti, 129 - 20141 Milan (Italy)
PHONE: +39 02 566011
FAX: +39 02 70048590
E-mail: aimgroupinternational.com

Unrestricted educational grant of





UNDER THE AUSPICES OF:

Dear Colleagues and Friends,

Welcome to the *5th International Conference on Future Trends in the Treatment of Brain Tumors*.

Launched in 2001, this international conference aims to foster the advancement of scientific knowledge that may ultimately result in a better prognosis for our patients. It provides an important forum for the exchange of knowledge and experience amongst the clinicians and researchers involved in brain tumour research and patient management. Gliomas are malignant diseases associated with poor prognosis and they are a key focus area for cancer research. However, despite significant advances in standard therapy, new treatments are urgently needed.

Accelerating the transition of promising laboratory findings *from bench to bedside* is providing exciting results – from clinical trials right through to point-of-care patient applications. The identification of oncogenic driver mutations and the underlying sensitivity to novel agents has led to a surge of interest in identifying additional targetable oncogenes in gliomas. A number of new potentially oncogenic gene alterations have been characterized in recent years, including IDH1/2 mutations. During this conference, we will discuss the prevalence of these genetic alterations, as well as the potential prognostic role in gliomas.

Knowledge of aberrant signalling pathways in gliomas has provided hope for new potential therapeutic targets. Many preclinical studies use brain tumours such as glioma as a model of angiogenesis, and recent findings have indicated that vascular endothelial growth factor (VEGF) plays a role in the development of gliomas. These neoplasms are highly vascular and elevated expression levels of VEGF have been correlated with biologic aggressiveness and poorer clinical outcomes. On the other hand, angiogenesis inhibition in primary and recurrent GBM is a potentially important treatment pathway that could provide meaningful health outcomes to patients.

Innovative therapeutic approaches are based on a greater understanding of molecular and cellular biology, and this educational event will review the very latest basic research findings. The internationally renowned speakers at this conference will also explore the clinical aspects of current neuro-oncology research, neuroradiological response evaluation, quality of life issues and comprehensive patient care that takes into account the patient's needs.

I look forward to joining you in the enchanting city of Bologna to discuss these important topics. I am confident that together we can make this conference an enjoyable and collaborative event where we can share our scientific and clinical knowledge in the hope of improving our patients' lives.

Yours sincerely,

Alba A. Brandes



CHAIRPERSON

Alba A. Brandes, Dept. of Medical Oncology, AUSL - IRCCS Institute of Neurological Sciences, Bologna, Italy

FACULTY

Raffaele Agati, Dept. of Neuroradiology, AUSL - IRCCS Institute of Neurological Sciences, Bologna, Italy

Giovanni Apolone, IRCCS Arcispedale S. Maria Nuova Hospital, Reggio Emilia, Italy

Carmen Balaña Quintero, Dept. of Medical Oncology, ICO - Hospital Germans Trias i Pujol, Badalona, Spain

Agostino Baruzzi, Scientific Director, IRCCS Institute of Neurological Sciences, Bologna, Italy

Tracy T. Batchelor, Stephen E. and Catherine Pappas Center for Neuro-Oncology Massachusetts General Hospital Cancer Center, Boston, USA

Brigitta Baumert, MediClin Robert Janker Klinik, Dept. Radiotherapy and Radiation-Oncology & University of Bonn Med Centre, Cooperation Unit Neuro-Oncology, Maastricht, The Netherlands

Antoine Carpentier, Dept. of Neurology, Avicenne Hospital, Paris XIII University, Bobigny, France

Oliver Chinot, Dept. of Neuro-Oncology, Timone Center University Hospital, University of the Mediterranean, Marseille, France

John De Groot, Dept. of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA

Lisa M. DeAngelis, Dept. of Neurology, Memorial Sloan-Kettering Cancer Center (MSKCC) & Professor of Neurology, Weill Medical College of Cornell University, New York, USA

Gaetano Finocchiaro, Dept. of Molecular Neuro-Oncology, IRCCS Foundation, Besta Neurological Institute, Milan, Italy

Pim J. French, Dept. of Neurology, Erasmus MC Cancer Center, Rotterdam, The Netherlands

Giovanni P. Frezza, Dept. of Oncological Radiotherapy, AUSL - IRCCS Institute of Neurological Sciences, Bologna, Italy

Felice Giangaspero, Institute of Pathological Anatomy, "Umberto I" University Hospital, University "La Sapienza" of Rome, Italy

Mark Gilbert, Dept. of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA

Stuart Grossman, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA

Stefano M. Magrini, Dept. of Radiation Oncology, Spedali Civili Hospital, Brescia, Italy

Warren Mason, The Gerry & Nancy Pencer Brain Tumor Centre, Princess Margaret Hospital, University of Toronto, Canada

Kathy Oliver, Co-Director, International Brain Tumor Alliance (IBTA), London, UK

Andrea Pace, Neurology Unit, Regina Elena National Cancer Institute, Rome, Italy

Josef Pichler, Internal Medicine and Neuro-Oncology, Landesnervenklinik Linz, Austria

David Reardon, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, USA

Francesco Ripa Di Meana, General Director, AUSL Bologna, Italy

Fausto Roila, Dept. of Oncology, S. Maria Hospital, Terni, Italy

Marc Sanson, Dept. of Neurology, Pitié-Salpêtrière Hospital, University Pierre and Marie Curie, Paris, France

Frank Saran, Dept. of Radiotherapy, Royal Marsden Hospital NHS Trust, Sutton, Surrey, UK

Carmelo Sturiale, Dept. of Neurosurgery, AUSL - IRCCS Institute of Neurological Sciences, Bologna, Italy

Walter Taal, Dept. of Neurology/Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, The Netherlands

Martin J. Taphoorn, Dept. of Neurology, Medical Center Haaglanden, The Hague Dep. of Neurology, VU University Medical Center, Amsterdam, The Netherlands

Martin J. Van den Bent, Dept. of Neurology/Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, The Netherlands

Michael Weller, Dept. of Neurology, University Hospital Zurich, Switzerland

Patrick Y. Wen, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, USA

Wolfgang Wick, Dept. of Neuro-Oncology, Heidelberg University Hospital, Heidelberg, Germany



5th INTERNATIONAL CONFERENCE ON FUTURE TRENDS IN THE TREATMENT OF BRAIN TUMORS

November 8th- 9th 2013, Hotel Royal Carlton, Bologna (Italy)

- 12:00 p.m. Welcome lunch
- 1:00 p.m. Participants registration
- 1:10 p.m. Welcome address
A. Baruzzi (Bologna), F. Ripa di Meana (Bologna)
- 1:20 p.m. Introduction
A.A. Brandes (Bologna)

SESSION I

GLIOBLASTOMA

Moderators: **P.J. French (Rotterdam), G.P. Frezza (Bologna), W. Mason (Toronto), F. Saran (London)**

- 1:30 p.m. Primary and secondary glioblastoma
F. Giangaspero (Rome)
- 1:50 p.m. The mechanism of anti-angiogenic inhibitor therapies in glioblastoma
J. De Groot (Houston)
- 2:10 p.m. New approaches to the treatment of newly diagnosed GBM patients
O. Chinot (Marseille)
- 2:30 p.m. New therapeutic approaches for newly diagnosed GBM patients: RTOG perspectives
M. Gilbert (Houston)
- 2:50 p.m. How to interpret clinical trials in newly diagnosed GBM patients
W. Wick (Heidelberg)

- 3:10 p.m. Discussion
- 3:40 p.m. Coffee break

SESSION II

Moderators: **A. Carpentier (Bobigny), F. Roila (Terni)**

- 4:00 p.m. Future trials in newly diagnosed GBM
A.A. Brandes (Bologna)
- 4:20 p.m. Future trials in elderly GBM
M. Weller (Zurich)
- 4:40 p.m. Discussion

SESSION III

Moderators: **G. Apolone (Reggio Emilia), A. Pace (Rome)**

- 4:55 p.m. Quality of life in gliomas
M.J. Taphoorn (The Hague)
- 5:15 p.m. Quality of life and clinical trial outcomes in newly diagnosed GBM
W. Mason (Toronto)
- 5:35 p.m. Clinical management of anti-angiogenic inhibitor therapy in patients with brain tumours
S. Grossman (Baltimore)
- 5:55 p.m. The brain tumour patient and caregiver: what really matters on the journey?
K. Oliver (IBTA, London)
- 6:15 p.m. Discussion
- 6:30 p.m. Close day 1



5th INTERNATIONAL CONFERENCE ON FUTURE TRENDS IN THE TREATMENT OF BRAIN TUMORS

November 8th- 9th 2013, Hotel Royal Carlton, Bologna (Italy)

SESSION I

RECURRENT GLIOBLASTOMA: EVALUATION OF PROGRESSION

Moderators: *R. Agati (Bologna), C. Balaña Quintero (Badalona),
W. Taal (Rotterdam)*

08:45 a.m. Rano criteria
P.Y. Wen (Boston)

09:05 a.m. Nano criteria
D. Reardon (Boston)

09:25 a.m. Glioblastoma recurrence: news from ASCO 2013
T.T. Batchelor (Boston)

09:45 a.m. Discussion

AWARD SESSION

Moderators: *A.A. Brandes (Bologna), S.M. Magrini (Brescia),
J. Pichler (Linz)*

10:00 a.m. Award for the best clinical work published in the last 3 years

10:30 a.m. Coffee break

SESSION II

LOW GRADE AND ANAPLASTIC GLIOMAS

Moderators: *G. Finocchiaro (Milan), S. Grossman (Baltimore),
C. Sturiale (Bologna)*

10:45 a.m. Can molecular markers help with decision-making?
M. Sanson (Paris)

11:05 a.m. Anaplastic oligodendroglioma: advances and treatment options
M. J. Van den Bent (Rotterdam)

11:25 a.m. Anaplastic astrocytomas: advances and treatment options
W. Wick (Heidelberg)

11:45 a.m. Low-grade gliomas: advances and treatment options
B. Baumert (Maastricht)

12:05 p.m. The treatment of brain tumours in 2020
L.M. DeAngelis (New York)

12:25 p.m. Discussion

12:40 p.m. Take home messages
A.A. Brandes (Bologna)

12:50 p.m. CME questionnaire. Meeting close

1:00 p.m. Lunch buffet





SCIENTIFIC INFORMATION

OFFICIAL LANGUAGE

English

SLIDES

Only computer video projection will be available. Other requirements should be communicated to the Scientific Secretariat as soon as possible. The presentations should be handed into the Slide Center on pen drive one hour before the beginning of the session, and collected at the end.

BADGE

All registered participants, speakers and attendants will be given a badge which they must wear to be admitted to the scientific sessions.

ATTENDANCE CERTIFICATE

A certificate will be given to all attendants at the end of the conference.

CME

Accreditation has been requested for MDs working in oncology, neuro-oncology, neurology, radiotherapy, neuro-radiology, pathological anatomy departments and for nurses.

GENERAL INFORMATION

CONFERENCE VENUE

SALA IMPERIALE

HOTEL ROYAL CARLTON

VIA MONTEBELLO 8, 40121 BOLOGNA

PHONE +39 051 – 249361

HOW TO REACH THE CONFERENCE VENUE

The Royal Hotel Carlton is in the centre of Bologna, near the pedestrian area, outside the restricted traffic zone and just a short walk from the railway station and Piazza Maggiore.

Walking distance: Bologna railway station.

By taxi: 15 minutes (5 km) from Bologna airport.

By car: to reach the hotel using satellite navigation, it should be set for Via Milazzo 6 to avoid the restricted traffic zone.

REGISTRATION

The registration is free of charge. Preference will be given to pre-registered attendants. Please return the pre-registration form to the Scientific Secretariat.

McCANN Complete Medical

Via Aosta 4/a, 20155 Milan, Italy

PHONE: +39 02 5416951 FAX: +39 02 54169554;

E-mail: segreteria@complete-italy.it



REGISTRATION FORM

The registration is free of charge.

Please return this form to the Scientific Secretariat:

McCANN Complete Medical

Via Aosta 4/a, 20155 Milan, Italy

PHONE: +39 02 5416951 FAX: +39 02 54169554

E-mail: segreteria@complete-italy.it

LAST NAME

FIRST NAME

POSITION TITLE

INSTITUTION

PRIVATE ADDRESS

ZIP CODE

CITY

STATE/PROVINCE

COUNTRY

PHONE

FAX

MOBILE PHONE

EMAIL

TAX PAYER'S NUMBER (FISCAL CODE)

Signing this form and well informed on the Legislative Decree n. 196/2003 concerning "Personal data processing", I authorize McCann Complete Medical until written revocation, to process and divulge my personal data within the limits of the above-mentioned law and in accordance with the procedure laid down by the law. I give my assent provided that McCann Complete Medical complies with the regulations in force.

I do not want that my personal data are divulged to third parties.

Date

Signature



YOUNG INVESTIGATOR AWARD

INTRODUCTION

The young investigator Award illustrates the dedication of the [5th International Congress on future trends in the treatment of brain tumors](#) to support original research and scientific excellence. The Young Investigator Award is conferred to one young Medical Oncologist, not older than 40 years of age by the end of the year in which the Award is given, in recognition of her or his scientific publications on the treatment of brain tumours. The award is given on the basis of a selection from submissions received from applicants.

HOW TO APPLY

An applicant must submit the following information in the format below:

- One original paper, published or accepted for publication, in an international peer-reviewed journal in the last three years. The candidates must be the first author.
- An up-to-date CV and a list of publications.

ELIGIBILITY

All applications must be submitted electronically, by ordinary mail or FAX, to the Scientific Secretary at:

McCann Complete Medical - Via Aosta 4/a - 20155 Milan, Italy

Object: Young Investigator Award – 5th International Conference on Future Trends in the Treatment of Brain Tumors

FAX: +39 02 54169554

E-mail: segreteria@complete-italy.it

All applicants will be acknowledged by email.

EVALUATION

The decisions taken by the Committee are based on the overall quality of the candidate's CV, and especially on the original publication submitted by each applicant. The successful applicant will be notified by the Committee before the "5th International Congress on future trends in the treatment of brain tumors" and will be awarded during the Congress.



**5th INTERNATIONAL CONFERENCE
ON FUTURE TRENDS IN THE
TREATMENT OF BRAIN TUMORS**

November 8th-9th 2013, Hotel Royal Carlton, Bologna (Italy)

YOUNG INVESTIGATOR AWARD

APPLICATION FORM

(To be submitted electronically to segreteria@complete-italy.it)

NAME OF APPLICANT _____

PROFESSIONAL ADDRESS _____

DATE OF BIRTH / / _____

TELEPHONE No National code Regional code Number

FAX No National code Regional code Number

E-MAIL _____

SUBMITTED PAPER (authors, title, journal reference including first and last page numbers)

1. _____

Please send your completed application form and supporting documents
ELECTRONICALLY to the Scientific Secretariat: segreteria@complete-italy.it

Checklist of items to include:

- Applicant's CV
- Copy of the paper (pdf)

Date _____

Signature _____



